Literature DB >> 18656554

Differential effects of furnidipine and its active metabolites in rat isolated working heart.

Tadeusz F Krzemiński1, Damian Hudziak, Andrzej W Sielańczyk, Maurycy Porc, Agnieszka Kedzia.   

Abstract

1,4,-dihydropyridines, belonging to the class of "privileged structures", are known to protect the heart from stunning, ischemia and ventricular arrhythmias and mainly used in hypertension. The aim of this study was to compare the continuous infusion of parent drug, furnidipine, with its two active metabolites (M-2; M-3) in rat isolated working heart model, where the following parameters were measured and calculated: heart rate, preload pressure, aortic systolic and diastolic pressures (AoD), as well as +/-dP/dt, aortic (AF) and coronary flow (CF), oxygen and carbon dioxide partial pressures and pH values in pulmonary effluent, myocardial oxygen consumption. At first, the optimal vasodilatatory dose of M-2 was estimated and afterwards it was compared with equivalent doses of both remaining substances. The strongest vasodilatatory effects were observed after the lowest dose of M-2 was used (10(-7) M), at the same time being without marked influence on pressure parameters. The pro-drug evoked significantly weaker influence on both flows. Furthermore, furnidipine significantly reduced AoD and AF in comparison to control as well as +dP/dt in comparison to the initial values, while M-2 did not. Both metabolites caused a significant CF increase, but M-3 additionally the AoS and AoD decrease in comparison to the control. Regarding clear differences in the measured parameters between the pro-drug and its metabolites found, the obtained results allow to claim that the metabolites vs. furnidipine possess a beneficial influence. The distinct flow shift from aorta into the coronaries was observed only after M-2 and to a lesser extent--M-3. The cardio-depressant potency of both metabolites is overcome by advantageous vasodilatatory effect. M-2, being a final product, easier to control and at the same time a precursor of the new chemical class of therapeutics, is promising as a cardio-protective agent.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18656554     DOI: 10.1016/j.vph.2008.06.005

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  3 in total

1.  Cardiomyopathy development protection after myocardial infarction in rats: Successful competition for major dihydropyridines' common metabolite against captopril.

Authors:  Katarzyna A Mitręga; Adrianna M Spałek; Jerzy Nożyński; Maurycy Porc; Magdalena Stankiewicz; Tadeusz F Krzemiński
Journal:  PLoS One       Date:  2017-06-21       Impact factor: 3.240

2.  Differential effects of furnidipines' metabolites on reperfusion-induced arrhythmias in rats in vivo.

Authors:  Katarzyna A Mitrega; Maurycy Porc; Tadeusz F Krzeminski
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

3.  Dihydropyridines' metabolites-induced early apoptosis after myocardial infarction in rats; new outlook on preclinical study with M-2 and M-3.

Authors:  Katarzyna A Mitręga; Jerzy Nożyński; Maurycy Porc; Adrianna M Spałek; Tadeusz F Krzemiński
Journal:  Apoptosis       Date:  2016-02       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.